Sou Hu Cai Jing·2026-01-07 11:55Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [1][2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [1]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [1]. - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [1]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [1]. - The net profit for Q3 2025 was 77.06 million yuan, showing a staggering increase of 531.12% year-on-year [1]. - The non-recurring net profit for Q3 2025 was 74.52 million yuan, up 439.4% year-on-year [1]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [1]. - The gross profit margin is reported at 67.27% [1]. Market Activity - As of January 7, 2026, the stock closed at 25.64 yuan, with a slight increase of 0.31% [1]. - The turnover rate was 0.62%, with a trading volume of 18,000 hands and a transaction amount of 46.3441 million yuan [1]. - On January 7, the net inflow of main funds was 159,600 yuan, accounting for 0.34% of the total transaction amount [1]. - Retail investors experienced a net outflow of 201,990 yuan, representing 4.36% of the total transaction amount [1]. - Over the past 90 days, 8 institutions have rated the stock as a buy, with an average target price of 31.7 yuan [2].